<DOC>
	<DOCNO>NCT02445807</DOCNO>
	<brief_summary>This study compare efficacy safety DFD-06 Cream Vehicle Cream topical treatment moderate severe plaque psoriasis 3 , 7 , 14 day treatment .</brief_summary>
	<brief_title>A Study Efficacy Safety DFD-06 Cream Treatment Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description>This study multicenter ( approximately 30 site ) , randomize , vehicle-controlled , double-blind , parallel group design . Approximately 264 subject moderate severe plaque psoriasis randomize treatment DFD-06 Cream Vehicle Cream . Subjects use study product twice daily 14 day . Subject visit schedule Screening , Baseline ( Day 1 ) Days 4 , 8 , 15 . Clinical determination disease severity perform use total sign score ( TSS ) target lesion Investigator Global Assessment ( IGA ) overall severity .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Subject understands study procedure agree participate give write informed consent . Subjects must willing authorize use disclosure protect health information collect study . 2 . Subject must least 18 year age . 3 . Subject must present clinical diagnosis stable ( least 3 month ) plaquetype psoriasis . 4 . Subject psoriasis involve 3 % great BSA , include face , scalp , groin , axillae intertriginous area . 5 . Subject must IGA grade 3 4 ( moderate severe ) Baseline Visit . 6 . Female subject childbearing potential must agree use contraception study include abstinence adequate secondary option subject become sexually active . All woman childbearing potential must complete urine pregnancy test ( test must sensitivity least 25mIU/ml human chorionic gonadotropin ) Baseline Visit ( Visit 2 ) test result must negative eligible enrollment . 7 . Subject must good general health determine investigator support medical history normal clinically significant abnormal vital sign ( blood pressure pulse ) . 1 . Current diagnosis unstable form psoriasis include guttate , erythrodermic , exfoliative pustular psoriasis . 2 . Other inflammatory skin disease may confound evaluation plaque psoriasis ( e.g. , atopic dermatitis , contact dermatitis , tinea corporis ) . 3 . Presence pigmentation , extensive scarring , pigment lesion sunburn could interfere rating efficacy parameter . 4 . History psoriasis unresponsive biological topical treatment . 5 . History organ transplant require immunosuppression , HIV , immunocompromised state . 6 . Use within 180 day prior Baseline Visit biologic treatment psoriasis ( e.g. , infliximab , adalimumab , etanercept , ustekinumab , secukinumab , alefacept ) . 7 . Have receive treatment type cancer within 5 year Baseline Visit except skin cancer cervical cancer ( situ ) allow least 1 year Baseline Visit . 8 . Use within 60 day prior Baseline Visit : 1 ) systemic topical immunosuppressive drug ( e.g. , tacrolimus , pimecrolimus ) , 2 ) systemic antipsoriatic treatment ( e.g. , methotrexate , cyclosporine , hydroxyurea ) 3 ) oral retinoids ( e.g. , acitretin , isotretinoin ) . 9 . Use within 30 day prior Baseline Visit : 1 ) systemic steroid , 2 ) PUVA therapy , 3 ) systemic antiinflammatory agent ( e.g. , mycophenolate mofetil , sulfasalazine , 6thioguanine ) , 4 ) UVB therapy . Inhaled , intraocular , intranasal steroid allow . 10 . Use within 14 day prior Baseline Visit : 1 ) topical antipsoriatic drug ( e.g. , salicylic acid , anthralin , coal tar , calcipotriene ) , 2 ) topical retinoids ( e.g. , tazarotene , tretinoin ) 3 ) topical corticosteroid . 11 . Subjects participate study investigational drug 60 day prior Baseline Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>